JP2018536433A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536433A5
JP2018536433A5 JP2018541546A JP2018541546A JP2018536433A5 JP 2018536433 A5 JP2018536433 A5 JP 2018536433A5 JP 2018541546 A JP2018541546 A JP 2018541546A JP 2018541546 A JP2018541546 A JP 2018541546A JP 2018536433 A5 JP2018536433 A5 JP 2018536433A5
Authority
JP
Japan
Prior art keywords
protein
hbv
nucleotide sequence
antigenic fragment
arenavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018541546A
Other languages
English (en)
Japanese (ja)
Other versions
JP6914950B2 (ja
JP2018536433A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/076591 external-priority patent/WO2017076988A1/en
Publication of JP2018536433A publication Critical patent/JP2018536433A/ja
Publication of JP2018536433A5 publication Critical patent/JP2018536433A5/ja
Priority to JP2021116562A priority Critical patent/JP2021182922A/ja
Application granted granted Critical
Publication of JP6914950B2 publication Critical patent/JP6914950B2/ja
Priority to JP2023180121A priority patent/JP7777907B2/ja
Priority to JP2025194235A priority patent/JP2026036693A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018541546A 2015-11-04 2016-11-03 B型肝炎ウイルスに対するワクチン Active JP6914950B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021116562A JP2021182922A (ja) 2015-11-04 2021-07-14 B型肝炎ウイルスに対するワクチン
JP2023180121A JP7777907B2 (ja) 2015-11-04 2023-10-19 B型肝炎ウイルスに対するワクチン
JP2025194235A JP2026036693A (ja) 2015-11-04 2025-11-13 B型肝炎ウイルスに対するワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250639P 2015-11-04 2015-11-04
US62/250,639 2015-11-04
PCT/EP2016/076591 WO2017076988A1 (en) 2015-11-04 2016-11-03 Vaccines against hepatitis b virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021116562A Division JP2021182922A (ja) 2015-11-04 2021-07-14 B型肝炎ウイルスに対するワクチン

Publications (3)

Publication Number Publication Date
JP2018536433A JP2018536433A (ja) 2018-12-13
JP2018536433A5 true JP2018536433A5 (enExample) 2020-03-26
JP6914950B2 JP6914950B2 (ja) 2021-08-11

Family

ID=57249796

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018541546A Active JP6914950B2 (ja) 2015-11-04 2016-11-03 B型肝炎ウイルスに対するワクチン
JP2021116562A Pending JP2021182922A (ja) 2015-11-04 2021-07-14 B型肝炎ウイルスに対するワクチン
JP2023180121A Active JP7777907B2 (ja) 2015-11-04 2023-10-19 B型肝炎ウイルスに対するワクチン
JP2025194235A Pending JP2026036693A (ja) 2015-11-04 2025-11-13 B型肝炎ウイルスに対するワクチン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021116562A Pending JP2021182922A (ja) 2015-11-04 2021-07-14 B型肝炎ウイルスに対するワクチン
JP2023180121A Active JP7777907B2 (ja) 2015-11-04 2023-10-19 B型肝炎ウイルスに対するワクチン
JP2025194235A Pending JP2026036693A (ja) 2015-11-04 2025-11-13 B型肝炎ウイルスに対するワクチン

Country Status (20)

Country Link
US (2) US11214598B2 (enExample)
EP (2) EP4177348A1 (enExample)
JP (4) JP6914950B2 (enExample)
KR (2) KR20250107977A (enExample)
CN (2) CN115948467A (enExample)
AU (3) AU2016348675B2 (enExample)
CA (1) CA3003557A1 (enExample)
DK (1) DK3371316T3 (enExample)
ES (1) ES2934698T3 (enExample)
FI (1) FI3371316T3 (enExample)
HR (1) HRP20221474T1 (enExample)
HU (1) HUE060648T2 (enExample)
IL (2) IL259077B2 (enExample)
LT (1) LT3371316T (enExample)
MX (2) MX2018005569A (enExample)
PL (1) PL3371316T3 (enExample)
PT (1) PT3371316T (enExample)
SG (1) SG11201803474UA (enExample)
SI (1) SI3371316T1 (enExample)
WO (1) WO2017076988A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2604695T3 (pl) 2007-12-27 2023-04-11 Universität Zürich Cząstka arenawirusa z defektem replikacji
DK3077519T3 (en) 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
HUE051390T2 (hu) 2014-11-13 2021-03-01 Univ Geneve Háromszegmensû arenavírusok mint vakcinavektorok
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
CN115948467A (zh) * 2015-11-04 2023-04-11 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
CA3003548A1 (en) 2015-11-12 2017-05-18 Hookipa Biotech Ag Arenavirus particles as cancer vaccines
MA46535A (fr) 2016-10-14 2019-08-21 Prec Biosciences Inc Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
JP2022010187A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
JP2022010188A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
AU2020297011A1 (en) * 2019-06-18 2022-02-10 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof
EP3986454A1 (en) * 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
US20220380805A1 (en) * 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
DK4069729T3 (da) 2019-12-06 2025-04-07 Prec Biosciences Inc Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
JP7711068B2 (ja) 2019-12-24 2025-07-22 カルナバイオサイエンス株式会社 ジアシルグリセロールキナーゼ調節化合物
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
KR102375703B1 (ko) 2020-07-28 2022-03-17 경북대학교 산학협력단 사물 인터넷 환경에서 CoAP 기반의 데이터 스트리밍 방법 및 통신 시스템
BR112023019365A2 (pt) 2021-03-23 2023-12-26 Hookipa Biotech Gmbh Segmento s de arenavírus, cdna, vetor de expressão de dna, célula hospedeira, partícula de arenavírus trissegmentada, método para gerar uma partícula de arenavírus trissegmentada, composição farmacêutica, método para tratar câncer de próstata e kit
US20250034213A1 (en) * 2021-04-21 2025-01-30 La Jolla Institute For Immunology Engineered arenavirus glycoprotein compositions, methods and use thereof
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用
EP4337223A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
AU2024343172A1 (en) 2023-09-15 2026-03-05 Gilead Sciences, Inc. Arenavirus formulations, methods and uses thereof
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH1084967A (ja) * 1996-09-19 1998-04-07 Fujirebio Inc B型肝炎のe抗原
AU770225B2 (en) * 1998-12-04 2004-02-19 Biogen Idec Ma Inc. HBV core antigen particles with multiple immunogenic components attached via peptide ligands
FR2803599B1 (fr) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
US20100183652A1 (en) * 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
WO2006125983A1 (en) * 2005-05-23 2006-11-30 Oxxon Therapeutics Ltd Compositions for inducing an immune response against hepatitis b
CN101037476A (zh) * 2006-03-15 2007-09-19 复旦大学 一种用于制备抗体化乙肝疫苗的融合蛋白及其载体
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
CA2673870A1 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
PL2604695T3 (pl) * 2007-12-27 2023-04-11 Universität Zürich Cząstka arenawirusa z defektem replikacji
KR20120052352A (ko) 2009-08-07 2012-05-23 트랜스진 에스.에이. Hbv 감염을 치료하는 조성물
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
EP3266464A3 (en) * 2011-02-12 2018-03-14 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
CN110042110A (zh) 2012-01-24 2019-07-23 桑福德健康公司 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸
ES2751423T3 (es) 2013-03-15 2020-03-31 Univ Geneve Vacunas antimicobacterianas
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
DK3077519T3 (en) 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
BR112017005744B1 (pt) 2014-09-22 2023-11-28 Regents Of The University Of Minnesota "vírus pichinde geneticamente manipulado, método de fabricação e uso do mesmo, partícula viral infecciosa, composição, coleção de vetores, sistema de genética reversa e método de uso do mesmo"
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
HUE051390T2 (hu) * 2014-11-13 2021-03-01 Univ Geneve Háromszegmensû arenavírusok mint vakcinavektorok
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
EP3365005B1 (en) 2015-10-23 2025-04-09 Institut Pasteur Recombinant mopeia virus and vaccine platform
CN115948467A (zh) 2015-11-04 2023-04-11 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
CA3003548A1 (en) 2015-11-12 2017-05-18 Hookipa Biotech Ag Arenavirus particles as cancer vaccines
US10980877B2 (en) 2016-04-28 2021-04-20 The University Of Chicago Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen
IL314272A (en) 2016-05-18 2024-09-01 Hookipa Biotech Gmbh Three-segmented PICHINDE viruses as vaccine vectors
JP2019533690A (ja) 2016-11-04 2019-11-21 ホオキパ バイオテック ジーエムビーエイチ 癌ワクチンとしての複製欠損性アレナウイルス粒子及び3セグメント型アレナウイルス粒子
AU2018247958A1 (en) 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors

Similar Documents

Publication Publication Date Title
JP2018536433A5 (enExample)
JP2021182922A5 (enExample)
FI3371316T3 (fi) Rokotteita hepatiitti b -virusta vastaan
JP6227094B2 (ja) 複製欠損アレナウイルスベクター
Hanke et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
Sominskaya et al. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes
JP2019519252A5 (enExample)
JP2017503482A5 (enExample)
JP2017535267A5 (enExample)
JP2017527557A5 (enExample)
TW201311901A (zh) Hbv聚合酶突變體
Woo et al. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes
JP2017515508A5 (enExample)
Raji et al. Virus-like particles in poultry disease: an approach to effective and safe vaccination
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
Kosinska et al. MVA-HBVac—A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination
NZ781654B2 (en) Vaccines against hepatitis b virus
CN1108306A (zh) 羧端带有前表面抗原1决定簇的重组乙肝疫苗
Thomson et al. Genetically modified hepatitis B surface antigen: A powerful vaccine technology for the delivery of disease-associated foreign antigens
Chen et al. HBsAg-vectored DNA vaccines elicit concomitant protective responses to multiple CTL epitopes relevant in human disease.
CN110055228A (zh) 用于乙肝病毒感染的重组巨细胞病毒与应用
Prince et al. Methodology Used in DNA-Based Prophylactic and Therapeutic Immunization Against Hepatitis B Virus in Chimpanzees
HK1192456A (en) Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
HK1151829B (en) Replication-defective arenavirus vectors